HD-PCI
2026
A Randomized Trial of Higher vs. Lower Dose Heparin for PCI (HD-PCI)
In patients undergoing elective PCI, a higher-dose unfractionated heparin policy did not reduce death, myocardial infarction or target vessel revascularisation at 30 days, or change major bleeding, compared with a lower-dose heparin policy.
Risultato
Efficacia: Death, myocardial infarction or target vessel revascularisation within 30 daysHR 1,29 (IC 95% 0,89-1,87)
Sicurezza: Major bleedingHR 1,03 (IC 95% 0,70-1,52)
Sotto 1 a favore di a higher-dose unfractionated heparin policy, sopra 1 a favore di a lower-dose heparin policy.
Tassi di eventi a higher-dose unfractionated heparin policy 1,2% vs a lower-dose heparin policy 1,0% (death, myocardial infarction or target vessel revascularisation within 30 days)
Riportato inoltre: An activated clotting time was recorded in 39.6% of procedures.
- Sottotema
- Periprocedural anticoagulation
- Disegno
- Cluster-randomised crossover trial of hospital-wide heparin policies for elective PCI (Population Health Research Institute, Canada). Each hospital alternates between a 100 U/kg and a 70 U/kg bolus of unfractionated heparin; outcomes come from linked PCI registries
- Arruolati
- 11.619 pazienti
- Fonte
- Jolly S, et al. Presented at TCT 2026, 1 November. Reported by TCTMD (CRF). Not yet published.
Discussione e critica
In a large cluster-crossover trial of elective PCI, a higher-dose heparin policy did not reduce 30-day ischaemic events or change major bleeding, and the source reports that the confidence interval excluded the benefit the trial was powered for. Follow-up was limited to 30 days, event rates were low, and centres rather than patients were randomised, so the trial compares hospital policies rather than individual dosing. The report gives hazard ratios without P values and does not describe blinding, adherence to the assigned policy or a net clinical outcome. These figures come from a news report of the presentation, not a peer-reviewed paper.